DAX21.371 -1,7%ESt505.202 -1,6%Top 10 Crypto14,51 -11,0%Dow44.545 -0,8%Nas19.627 -0,3%Bitcoin92.509 -2,8%Euro1,0262 -1,0%Öl77,02 +0,3%Gold2.809 +0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Volkswagen (VW) vz. 766403 Siemens Energy ENER6Y Tesla A1CX3T Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 Palantir A2QA4J BASF BASF11 Deutsche Bank 514000 Microsoft 870747 Bayer BAY001 BVB (Borussia Dortmund) 549309 Amazon 906866 Allianz 840400
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trump erlässt Strafzölle: DAX tiefer -- Bitcoin unter Druck -- Zwei Porsche-Vorstände vor dem Aus -- Bayer, Roche, Autowerte im Fokus
Top News
BÖRSE AKTUELL: DAX weit abgeschlagen - Trumps Zölle werden zur Belastungsprobe BÖRSE AKTUELL: DAX weit abgeschlagen - Trumps Zölle werden zur Belastungsprobe
Scholz kündigt Maßnahmen gegen mögliche US-Zölle an - Trump: Definitiv Handelszölle gegen die EU Scholz kündigt Maßnahmen gegen mögliche US-Zölle an - Trump: Definitiv Handelszölle gegen die EU
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Odyssey Acquisition Aktie

NeuKaufenVerkaufen
0,2980 EUR -0,0050 EUR -1,65 %
FSE
0,3100 EUR ±0,0000 EUR ±0,00 %
ASX
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone

Marktkap.38,70 Mio. EUR

Div. Rendite0,00%

WKNA3CTVP

ISINLU2355630455

SymbolBAIVF

Odyssey Acquisition Aktien News

DatumMeistgelesen
BusinesswireBenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission
BusinesswireBenevolentAI Appoints Kenneth Mulvany as Executive Chairman
BusinesswireBenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
BusinesswireBenevolentAI Interim Results for the Six Months Ended 30 June 2024
BusinesswireBenevolentAI: Appointment of Adviser
BusinesswireBenevolentAI: Leadership Team Change
BusinesswireBenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio
BusinesswireBenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit
BusinesswireBenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference
BusinesswireBenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected
BusinesswireBenevolentAI: Result of Annual General Meeting
BusinesswireBenevolentAI Provides an Update on Its Business Priorities
BusinesswireBenevolentAI: Publication of the Revised Agenda for the 2024 AGM
BusinesswireProposed Changes to BenevolentAI’s Board Composition
BusinesswireBenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers
BusinesswireBenevolentAI Appoints New Chief Technology Officer
BusinesswireBenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice
BusinesswireBenevolentAI: Notice of Preliminary Results
BusinesswireBenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer
BusinesswireBenevolentAI: Shareholder Letter December 2023
BusinesswireBenevolentAI: Directorate Change
BusinesswireBenevolentAI Signs Strategic Collaboration with Merck
BusinesswireBenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer
BusinesswireBenevolentAI Notice of Interim Results
BusinesswireBenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer
BusinesswireBenevolentAI Doses First Participants in Clinical Trial of BEN-8744; Targets PDE10, an AI-derived Novel Target for the Treatment of Ulcerative Colitis
BusinesswireBenevolentAI: Board Change
BusinesswireBenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
BusinesswireNew Preclinical Data on AI-Generated Target Identified in BenevolentAI and AstraZeneca Collaboration Presented at ATS 2023
BusinesswireBenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI
BusinesswireBenevolentAI Announces Top-Line Phase IIa Results for Its Topical pan-Trk Inhibitor BEN-2293 (1%) in Mild-to-Moderate Atopic Dermatitis
BusinesswireBenevolentAI Announces Publication of Convening Notice for AGM
BusinesswireBenevolentAI Achieves Further Milestones in AI-enabled Target Identification Collaboration With AstraZeneca
BusinesswireBenevolentAI Analyst / Investor Event
Wer­bung

Odyssey Acquisition News

Odyssey Acquisition News: auf dieser Seite finden Sie alle Odyssey Acquisition News und Nachrichten zur Odyssey Acquisition Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Odyssey Acquisition News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Odyssey Acquisition News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.